Modified Lipid Compounds for Cardiovascular Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Naturally occurring polyunsaturated fatty acids have limited stability and lack biological specificity, hindering their widespread use as therapeutic agents for conditions like cardiovascular and metabolic diseases.
Innovation Solution
Development of novel lipid compounds with specific chemical modifications, such as incorporating oxygen at the β-position and α-substituents, which enhance their biological activity and effectiveness in reducing lipid levels in dyslipidemic models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If naturally occurring polyunsaturated fatty acids are used as therapeutic agents, then they can regulate plasma lipid levels and affect physiological processes, but they have limited stability in vivo and lack biological specificity
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of polyunsaturated fatty acids through introducing oxygen at the β-position and adding α-substituents. These structural parameter changes enhance both the stability and biological specificity of the fatty acid derivatives, resolving the contradiction between reliability and harmful factors.
Solution Approach 2:
The invention creates composite molecular structures by combining polyunsaturated fatty acid chains with additional functional groups (oxygen at β-position and α-substituents). This composite approach generates new molecular entities that possess both improved stability and enhanced biological specificity, addressing both issues simultaneously.
2Reliability
If chemical modifications are introduced to enhance biological activity, then therapeutic effectiveness increases, but molecular complexity increases
Solution Approach 1:
The patent applies local quality by introducing modifications at specific positions (β-position and α-position) of the fatty acid chain rather than throughout the entire molecule. This localized approach enhances biological activity while minimizing overall molecular complexity, as only specific regions of the molecule are modified.
Solution Approach 2:
The invention uses parameter changes by modifying specific structural parameters (adding oxygen at β-position and substituents at α-position) to enhance biological activity. These targeted parameter changes achieve therapeutic effectiveness without requiring comprehensive molecular redesign, thus controlling complexity.
Data Source
Figure 1~2
Figure 3
AI summary
The present disclosure relates to lipid compounds of the general formula (I): R1-O-C(R2)(R3) -X (I) wherein R1 is a C10-C22 alkyl group, a C10-C22 alkenyl group having 1-6 double bonds, or a C10-C22 alkynyl group having 1-6 triple bonds; R2 and R3 are the same or different and may be chosen from different substituents; and X is a carboxylic acid or a derivative thereof, such as a carboxylic ester, a carboxylic anhydride, a phospholipid, triglyceride, or a carboxamide; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic, and inflammatory disease area.